Combination Chemotherapy with 1-Methyl-1-Nitrosourea and Cyclophosphamide in Metastatic Melanoma

1978 ◽  
Vol 64 (1) ◽  
pp. 89-94 ◽  
Author(s):  
Krsto Kolarić ◽  
Anton Roth ◽  
Vera Fuss
Keyword(s):  
Body Weight ◽  
Malignant Melanoma ◽  
Antitumor Activity ◽  
Lymph Nodes ◽  
Metastatic Melanoma ◽  
Combination Chemotherapy ◽  
Tumor Regression ◽  
Objective Response ◽  
Metastatic Malignant Melanoma ◽  
Melanoma Metastasis

Twenty one patients with advanced metastatic melanoma were treated with a combination of 1-methyl-1-nitrosourea (MNU) and cyclophosphamide. AH the patients had not previously been treated with cytostatics. MNU in the dose of 4 mg/kg and cyclophosphamide in the dose of 8 mg/kg body weight was administered daily. The drugs were given in 6 day cycles. Objective response (> 50% tumor regression) was obtained in 8 (38%) of the 21 treated patients, with 2 complete and 6 partial remissions. The duration of remission was 2–12 months (M = 6.2 months). Injections of MNU caused nausea and vomiting in approximately all the treated patients. Combination of these drugs, however, produced myelodepression in 33% of treated patients. This combination of drugs showed antitumor activity in metastatic malignant melanoma, particularly in melanoma metastasis of the lung, brain and lymph nodes and needs further investigation.

Combination Chemotherapy with Vinblastine, Bleomycin and Methotrexate in Dtic-resistant Metastatic Melanoma

1979 ◽  
Vol 65 (2) ◽  
pp. 237-240 ◽  
Author(s):  
Gianfranco Porcile ◽  
Mario Musso ◽  
Francesco Boccardo ◽  
Riccardo Rosso ◽  
Leonardo Santi
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Combination Chemotherapy ◽  
Response Rate ◽  
Objective Response ◽  
Complete Response

Fifteen patients with metastatic DTIC-resistant malignant melanoma were treated with vinblastine, bleomycin and methotrexate combination chemotherapy. Three patients showed an objective response (one complete response). The therapy was well tolerated and easy to administer. This combination appears to produce in DTIC-resistant patients a response rate similar to that obtained with DTIC.

Outpatient Biochemotherapy With Interleukin-2 and Interferon Alfa-2b in Patients With Metastatic Malignant Melanoma: Results of Two Phase II Cytokine Working Group Trials

2001 ◽  
Vol 19 (13) ◽  
pp. 3194-3202 ◽  
Author(s):  
L. E. Flaherty ◽  
M. Atkins ◽  
J. Sosman ◽  
G. Weiss ◽  
J. I. Clark ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Antitumor Activity ◽  
Phase Ii ◽  
Working Group ◽  
Objective Response ◽  
Interleukin 2 ◽  
Metastatic Malignant Melanoma ◽  
Phase Iii ◽  
Group 2 ◽  
Group 1

PURPOSE: The Cytokine Working Group performed a randomized phase II trial of two outpatient biochemotherapy regimens to identify an outpatient regimen with high antitumor activity and less toxicity than inpatient regimens which might be compared with chemotherapy or inpatient biochemotherapy regimens in future phase III trials. PATIENTS AND METHODS: Eighty-one patients with metastatic malignant melanoma received dacarbazine 250 mg/m2/d intravenously (IV) and cisplatin 25 mg/m2/d IV on days 1, 2, and 3, plus interferon (IFN) alfa-2b 5 mU/m2 subcutaneously (SC) on days 6, 8, 10, 13, and 15, given every 28 days. Interleukin-2 (IL-2) was given daily on days 6 to 10 and 13 to 15. In group 1, IV IL-2 was given at 18.0 MU/m2, and in group 2, SC IL-2 was given at 5.0 mU/m2. RESULTS: In group 1 (IV IL-2), there were five complete responses (CRs) and 11 partial responses (PRs) among 44 patients (objective response rate [ORR], 36%; 95% confidence interval [CI], 22% to 51%). In group 2 (SC IL-2), there was one CR and five PRs among the 36 patients (ORR, 17%; 95% CI, 4% to 29%). The median survival was 10.7 months in group 1 and 7.3 months in group 2. Eleven patients in group 1 and four patients in group 2 remain alive as of the last follow-up. Toxicities in both groups were similar. No patient required hospitalization for neutropenic fever. CONCLUSION: Biochemotherapy has activity in these outpatient regimens with acceptable toxicity. The antitumor activity observed with the IV IL-2 regimen seems similar to that of inpatient biochemotherapy regimens. If inpatient biochemotherapy regimens develop an established role in the management of melanoma, future phase III trial comparisons with this outpatient IV IL-2 regimen would be appropriate.

scholarly journals Diffuse melanosis secondary to metastatic melanoma in a Nelore bull

2021 ◽  
Vol 14 (3) ◽  
pp. 191-198
Author(s):  
Jacqueline de Jesus ◽  
◽  
Andrieli Bortolini ◽  
Gabriela de Almeida ◽  
Bárbara de Oliveira ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Urinary Bladder ◽  
Antibiotic Therapy ◽  
Lymph Nodes ◽  
Metastatic Melanoma ◽  
Clinical Signs ◽  
Metastatic Malignant Melanoma ◽  
Dark Urine ◽  
Spleen And Lymph Nodes ◽  
Black Discoloration

We report a case of diffuse melanosis secondary to metastatic malignant melanoma in a Nelore bull. Clinical signs included isolation from the herd, epistaxis, hyperthermia, pale ocular membranes, mucoid diarrhea and dark urine. Despite anti-inflammatory and antibiotic therapy, the bull died 45 days after the onset of the clinical signs. The most striking lesion was diffuse black discoloration to the visceral organs including liver, spleen, lungs, lymph nodes, and kidneys; all these affect organs were moderately enlarged”. The urine was black. Histologically, 50-80% of the parenchyma of the liver, spleen and lymph nodes was obliterated by aggregates of melanin-loaded neoplastic melanocytes. Those neoplastic cells also occurred within capillaries of the liver, spleen, lymph nodes, urinary bladder, lungs and kidneys. Immunohistochemistry of neoplastic melanocytes was positive for Melan A and PNL2 markers. Abundant brown to black pigment was found in melanophages in the lungs, confirmed by IBA1 immunohistochemistry.

scholarly journals Diffuse Melanosis and Ascites due to Metastatic Malignant Melanoma

2008 ◽  
Vol 8 ◽  
pp. 556-557 ◽  
Author(s):  
Elena Sendagorta ◽  
Angel Pizarro ◽  
Marta Feito ◽  
Matias Mayor ◽  
Paloma Ramírez ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Female Patient ◽  
Metastatic Malignant Melanoma ◽  
Current Evidence ◽  
Rare Entity ◽  
Skin Hyperpigmentation

We present a female patient who developed mucosal and skin hyperpigmentation due to metastatic malignant melanoma. Diffuse cutaneus melanosis is a rare entity that complicates a small percentage of metastatic melanomas, confering a fatal prognosis. We discuss briefly the current evidence on pathogenesis of melanosis arising from metastatic melanoma.

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

1991 ◽  
Vol 9 (8) ◽  
pp. 1403-1408 ◽  
Author(s):  
C I Falkson ◽  
G Falkson ◽  
H C Falkson
Keyword(s):  
Malignant Melanoma ◽  
Treatment Failure ◽  
Partial Remission ◽  
Performance Status ◽  
Objective Response ◽  
Metastatic Malignant Melanoma ◽  
Interferon Alfa ◽  
Time To Treatment Failure ◽  
Metastatic Sites

Sixty-four patients with histologically confirmed metastatic malignant melanoma were entered on a prospectively controlled randomized trial. Patients received dacarbazine (DTIC) alone or DTIC plus interferon (IFN) alfa-2b. Patients were reasonably balanced with respect to age, sex, performance status (PS), site of metastases, and number of metastatic sites. Objective response (complete plus partial remission [CR + PR]) was documented in six patients on DTIC and in 16 patients on DTIC plus IFN alfa-2b. Median time to treatment failure (TTF) and median survival are significantly better on the combination arm, with some long-term CRs observed. More toxicity was encountered in the combination arm, which was acceptable except in three patients where treatment was discontinued because of IFN toxicity.

Toxic and Therapeutic Activity of 4'-Epi-Doxorubicin

1982 ◽  
Vol 68 (2) ◽  
pp. 105-111 ◽  
Author(s):  
Valeria Bonfante ◽  
Fabrizio Villani ◽  
Gianni Bonadonna
Keyword(s):  
Malignant Melanoma ◽  
Antitumor Activity ◽  
Acute Toxicity ◽  
Phase I ◽  
Cardiac Toxicity ◽  
Objective Response ◽  
Therapeutic Activity ◽  
Cardiac Damage ◽  
Noninvasive Methods ◽  
Advanced Malignancy

A Phase I-II study with 4'-epi-doxorubicin (epi-DX) was performed in 108 patients with various types of advanced malignancy. The pattern of acute toxicity was similar to that of doxorubicin (DX). However, epi-DX was better tolerated than DX because of comparative lower incidence of vomiting, stomatitis, complete alopecia and severe myelosuppression. Cardiac toxicity was studied by utilizing noninvasive methods, and the electrocardiographic results suggested a slightly lower cardiac damage after epi-DX compared to DX. Antitumor activity was documented in a variety of neoplasms, and objective response was also observed in those considered refractory to DX such as malignant melanoma and renal cancer.

Phase 1 study to evaluate safety and efficacy of ipilimumab + nivolumab + external beam radiotherapy in patients with metastatic melanoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. TPS9591-TPS9591
Author(s):  
Michael Andrew Postow ◽  
Susan Jane Knox ◽  
Danielle McCabe ◽  
Mary J. Macri ◽  
Paul Schwarzenberger ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Metastatic Melanoma ◽  
Phase 1 ◽  
External Beam Radiotherapy ◽  
Objective Response ◽  
Palliative Therapy ◽  
Dose Fractionation ◽  
High Dose ◽  
Melanoma Metastasis ◽  
Open Label

TPS9591 Background: Immunotherapy (IMT) with checkpoint blocking antibodies has led to progress in metastatic melanoma with 3 FDA-approved drugs, including the combination of ipilimumab (IPI), a CTLA-4 antibody, and nivolumab (NIVO), a PD-1 antibody. Although radiotherapy (RT) is primarily used as local palliative therapy in metastatic melanoma, it also possibly affects systemic antitumor immunity. Preclinical data suggest RT alters the tumor microenvironment and renders tumor cells more susceptible to immunologically-mediated disease regression. These preclinical immunologic effects of RT have been shown to vary by RT dose and fractionation. We are now conducting the first clinical trial in patients to evaluate the triple combination of IPI + NIVO + RT using 2 different dose/fractionation schemes of RT. Methods: This ongoing Phase 1, open-label, multicenter study (NCT02659540) evaluates safety, efficacy, and immunologic effects of IPI + NIVO + RT in 18 patients with unresectable stage IV melanoma. Patients must have 1 melanoma metastasis that can be safely irradiated for palliative purposes and at least 1 measurable lesion that will not be irradiated. Patients receive concurrent IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks (Q3W) x 4, followed by NIVO monotherapy (240 mg Q2W), with RT initiated between the first and second doses of IPI + NIVO. In Cohort A, the irradiated metastasis receives a conventionally fractionated low dose of 30 Gy in 10 fractions of 3 Gy each over 2 weeks. If ≤7 of 9 patients (78%) in Cohort A have Grade 3/4 drug- or radiation-related adverse events, safety is deemed acceptable and Cohort B enrollment opens. In Cohort B, the irradiated metastasis receives a hypofractionated high dose of 27 Gy in 3 fractions of 9 Gy each over 2 weeks. The primary endpoint is safety. Secondary endpoints are objective response rate and disease control rate by RECIST and immune-related RECIST measured at Weeks 12 and 18, duration of response, progression-free survival, and overall survival. Exploratory endpoints include correlative studies of immunological effects. Enrollment opened on 05 Aug 2016. As of 31 Dec 2016, 4 patients are enrolled in Cohort A; enrollment is ongoing. Clinical trial information: NCT02659540.

TATTOO PIGMENT IN LYMPH NODES MIMICKING METASTATIC MALIGNANT MELANOMA

2003 ◽  
Vol 111 (6) ◽  
pp. 2120-2122 ◽  
Author(s):  
Tal Friedman ◽  
Melvin Westreich ◽  
Sharon Nofech Mozes ◽  
Arie Dorenbaum ◽  
Oscar Herman
Keyword(s):  
Malignant Melanoma ◽  
Lymph Nodes ◽  
Metastatic Malignant Melanoma ◽  
Tattoo Pigment

scholarly journals Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma

2019 ◽  
Vol 12 (1) ◽  
pp. 29-32 ◽  
Author(s):  
Keren Rouvinov ◽  
Karen Nalbandyan ◽  
Victor Kozlov ◽  
Nir Peled ◽  
Alexander Yakobson
Keyword(s):  
Malignant Melanoma ◽  
Aplastic Anemia ◽  
Metastatic Melanoma ◽  
Active Treatment ◽  
Melanoma Patient ◽  
Case Reports ◽  
Metastatic Malignant Melanoma ◽  
Line Treatment ◽  
Metastatic Melanoma Patient ◽  
Advanced Line

Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our knowledge, there are only three published case reports that have shown aplastic anemia in patients who have been treated by immunotherapy. This is the first report of a lethal aplastic anemia during nivolumab monotherapy in a metastatic melanoma patient.

Sign in / Sign up

Export Citation Format

Share Document